CRISPR research got much traction in 2020 when it began to be seen as a possible medical technology. CRISPR-Cas9 is used to edit genes and alter parts of DNA. Investors listened when companies started showing success with these trials because rare genetic disorders could be eliminated, and quality of life increased by using this technique. Is there an opportunity for us to ride the trend?
Read More
10/24/2021 by Dave Friedel Healthcare Equities InProgress